Diligence memo · auto-generated · as of July 2, 2026
Melinta Therapeutics, Inc. /New/
Melinta Therapeutics, Inc. /New/ looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Melinta Therapeutics, Inc. /New/ operates in Pharmaceuticals, based in NEW HAVEN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Melinta Therapeutics, Inc. /New/ has raised $347M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $138M on 2018-01-05.
Most recent recorded round closed around 2018-01-05.
Valuation (modeled)modeled
Provath models Melinta Therapeutics, Inc. /New/ at approximately $4.9B (range $656M–$10.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.10× the median modeled value of Series D+ Pharmaceuticals companies in 2016–2018 (11 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 8.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Concordia International Corp., Surterra Holdings, Inc./DE, Ironwood Pharmaceuticals Inc, Beam Therapeutics Inc., Tris Pharma, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.